University of Trieste   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Trieste Italy (1924)

Organization Overview

First Clinical Trial
1999
NCT00382343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

dott. Lorenzo Bevilacqua | Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste Trieste, TS, 34129, Italy | Institute for maternal and child health Burlo Garofolo | Institute for Maternal and Child Health IRCCS Burlo Garofol | Institute for Maternal and Child Health IRCCS Burlo Garofolo | Institute for maternal and child health - IRCCS "Burlo Garofolo", Trieste, Italy | Institute of Child Health IRCCS Burlo Garofolo, Trieste, Italy | IRCCS Burlo Garofolo | Univerisity of Trieste | University of Trieste

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdominal Pain (Phase 3)

Acute Pain (Phase 3)

Bronchiolitis (Phase 4)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Coronavirus Infections (Phase 3)

Crohn Disease (Phase 3)

Fractures, Bone (Phase 4)

Gastroenteritis (Phase 3)

Infections (Phase 4)

Inflammation (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Migraine Disorders (Phase 3)

Pain, Procedural (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 3)

Pyelonephritis (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Status Epilepticus (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 3)

Urinary Tract Infections (Phase 4)

Vesico-Ureteral Reflux (Phase 4)

Vomiting (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 33